行情

IBIO

IBIO

IBIO
AMEX

实时行情|Nasdaq Last Sale

1.140
-0.090
-7.32%
盘后: 1.140 0 0.00% 19:58 09/20 EDT
开盘
1.150
昨收
1.230
最高
1.187
最低
1.130
成交量
219.94万
成交额
--
52周最高
2.830
52周最低
1.030
市值
2.48亿
市盈率(TTM)
-7.1743
分时
5日
1月
3月
1年
5年
iBio 将参加 Cantor 2021 虚拟全球医疗保健会议
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that the C...
GlobeNewswire · 6小时前
iBio 将于 2021 年 9 月 27 日星期一报告 2021 财年第四季度和全年财务业绩并提供公司更新
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it wi...
GlobeNewswire · 15小时前
iBio 宣布参加 HC Wainwright 第 23 届年度全球投资大会
BRYAN, Texas, Sept. 07, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that it wi...
GlobeNewswire · 09/07 20:30
与竞争对手相比，iBio Inc. 股票周五表现不佳
marketwatch.com · 09/03 20:59
iBio Inc. 股价周三上涨，跑赢大盘
marketwatch.com · 09/01 20:59
iBio Inc. 股价周二保持稳定，仍跑赢大市
marketwatch.com · 08/31 20:59
iBio Inc. 股价周四下跌，跑输大市
marketwatch.com · 08/26 20:59
iBio 与 RubrYc 交易扩大免疫肿瘤学管道
Benzinga · 08/25 15:16
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解IBIO最新的财务预测，通过IBIO每股收益，每股净资产，每股现金流等数据分析IBIO近期的经营情况，然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测IBIO价格均价为2.500，最高价位3.000，最低价为2.000。
EPS
机构持股
总机构数: 16
机构持股: 33.22万
持股比例: 0.15%
总股本: 2.18亿
类型机构数股数
增持
4
1.41万
建仓
2
1.98万
减持
3
6,983
平仓
1
250
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.35%
制药与医学研究
-1.08%
高管信息
Chairman/President/Chief Executive Officer/Director
Thomas Isett
Chief Financial Officer/Chief Accounting Officer
Robert Lutz
Chief Operating Officer
Randy Maddux
Chief Scientific Officer
Martin Brenner
Treasurer/Secretary/Director
Robert Kay
Director
William Clark
Director
Evert Schimmelpennink
Independent Director
Linda Armstrong
Independent Director
Glenn Chang
Independent Director
James Hill
Independent Director
Alexandra Kropotova
Independent Director
John McKey
Independent Director
Gary Sender
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
IBIO 简况
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.

微牛提供Ibio Inc(AMEX-IBIO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的IBIO股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IBIO股票基本功能。